In-vivo generation of leukaemia-derived dendritic cells
- PMID: 15498715
- DOI: 10.1016/j.beha.2004.06.004
In-vivo generation of leukaemia-derived dendritic cells
Abstract
Adoptive immunotherapy with transfusion of donor lymphocytes in allogeneic stem cell chimeras has been successful in the treatment of recurrent chronic myelogenous leukaemia (CML) and some patients with acute myeloid leukaemia (AML). The hypothesis that the graft-vs-leukaemia effect (GVL) is promoted by leukaemia-derived dendritic cells has been supported by the concurrent treatment of patients with cytokines that are known to induce differentiation of leukaemia cells towards dendritic cells. In combination with donor lymphocyte transfusions, treatment with interferon-alpha and granulocyte-macrophage colony-stimulating factor has been studied in patients with recurrent CML and AML, and pre-emptively in patients with high-risk AML. Long-term remissions have been observed in cytokine-treated patients, indicating the beneficial effect of cytokine stimulation of GVL reactions. This is likely to be due to differentiation of leukaemia progenitor cells towards dendritic cells in vivo.
Similar articles
-
Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.Exp Hematol. 2006 Apr;34(4):475-85. doi: 10.1016/j.exphem.2005.12.012. Exp Hematol. 2006. PMID: 16569594
-
Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress.Crit Rev Immunol. 2001;21(1-3):147-55. Crit Rev Immunol. 2001. PMID: 11642601 Review.
-
In vitro cytokine-primed leukaemia cells induce in vivo T cell responsiveness in chronic myeloid leukaemia.Bone Marrow Transplant. 1998 Dec;22(12):1185-90. doi: 10.1038/sj.bmt.1701511. Bone Marrow Transplant. 1998. PMID: 9894722
-
Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia: implications for adoptive immunotherapy with T cells.Br J Haematol. 1996 Mar;92(3):587-94. Br J Haematol. 1996. PMID: 8616022
-
Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.Blood Rev. 2005 Nov;19(6):289-300. doi: 10.1016/j.blre.2004.09.002. Epub 2005 Apr 7. Blood Rev. 2005. PMID: 16275419 Review.
Cited by
-
Immunotherapy of myeloid leukaemia.Cancer Immunol Immunother. 2007 Jul;56(7):943-57. doi: 10.1007/s00262-006-0267-y. Epub 2006 Dec 20. Cancer Immunol Immunother. 2007. PMID: 17180671 Free PMC article. Review.
-
Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Front Immunol. 2017 Jun 7;8:496. doi: 10.3389/fimmu.2017.00496. eCollection 2017. Front Immunol. 2017. PMID: 28638379 Free PMC article. Review.
-
Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation.Cancer Immunol Immunother. 2019 Nov;68(11):1891-1899. doi: 10.1007/s00262-019-02406-9. Epub 2019 Oct 18. Cancer Immunol Immunother. 2019. PMID: 31628525 Free PMC article. Review.
-
Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL.Mol Ther Methods Clin Dev. 2021 Apr 9;21:621-641. doi: 10.1016/j.omtm.2021.04.004. eCollection 2021 Jun 11. Mol Ther Methods Clin Dev. 2021. PMID: 34095345 Free PMC article.
-
Clinical uses of GM-CSF, a critical appraisal and update.Biologics. 2008 Mar;2(1):13-27. doi: 10.2147/btt.s1355. Biologics. 2008. PMID: 19707424 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
